Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Oogenesis02:07

Oogenesis

70.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.8K
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

4.7K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.7K
Ovaries01:26

Ovaries

3.0K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
3.0K
Ovarian Cycle01:27

Ovarian Cycle

4.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.8K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.3K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.3K
Cancer02:18

Cancer

55.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

JCO clinical cancer informatics·2026
Same author

Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.

Oncogene·2026
Same author

Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework.

Journal of gynecologic oncology·2026
Same author

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Journal of gynecologic oncology·2026
Same author

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.

Nature communications·2026
Same author

Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Mar 7, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

卵巢癌是发生在卵巢中的癌症.

Clare L Scott1,2,3,4,5, Susana Banerjee6, Florence Joly7

  • 1Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. scottc@wehi.edu.au.

Nature reviews. Disease primers
|March 5, 2026
PubMed
概括

表皮卵巢癌 (EOC) 由于其异质性而带来诊断和治疗挑战. 针对性治疗的进展,如BRCA突变病例的PARP抑制剂,正在改善结果,但进一步的生物标志物研究至关重要.

更多相关视频

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

12.0K

相关实验视频

Last Updated: Mar 7, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

12.0K

科学领域:

  • 妇科瘤学 妇科瘤学
  • 分子病理学分子病理学
  • 癌症治疗方法 癌症治疗方法

背景情况:

  • 表皮卵巢癌 (EOC) 涵盖了各种疾病,其起源,分子特征和预后各不相同.
  • 特定EOC亚型的低发病率使诊断,证据生成和治疗开发复杂化.
  • 尽管有遗传倾向,但有效的查仍然难以捉摸,导致频繁的晚期诊断.

研究的目的:

  • 审查当前对上皮卵巢癌发病,诊断和管理的理解.
  • 为了突出EOC研究和临床护理的挑战,由于疾病异质性.
  • 讨论新兴的治疗策略和生物标志物验证的需要.

主要方法:

  • 对EOC病原体,遗传学和治疗方式的现有文献的审查.
  • 分析当前的管理策略,包括手术,化疗和向治疗.
  • 评估遗传易感性和分子特征在EOC中的作用.

主要成果:

  • EOCs表现出显著的异质性,具有不同的起源和分子形状.
  • 标准治疗包括手术和基于的化疗,有针对性的疗法显示出希望.
  • 聚 ((ADP-ribose) 聚合酶抑制剂改善了BRCA突变EOC患者的治疗结果.

结论:

  • 缺乏有效的EOC查,需要改进诊断和预后生物标志物.
  • 向治疗和免疫疗法显示出潜力,但需要进一步的研究和验证.
  • 针对翻译的临床试验对于推进EOC护理和开发有效治疗方法至关重要.